Cetrorelix: Difference between revisions

Jump to navigation Jump to search
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}))
Line 26: Line 26:


==References==
==References==
{{reflist}}
{{reflist|2}}


{{Sex hormones}}
{{Sex hormones}}

Revision as of 15:26, 4 September 2012


Cetrorelix
Clinical data
Pregnancy
category
  • US: X (Contraindicated)
Routes of
administration
Subcutaneous injection
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability85%
Protein binding86%
Elimination half-life62.8 hours / 3mg single dose
ExcretionLiver
Identifiers
CAS Number
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass1431.06 g/mol

WikiDoc Resources for Cetrorelix

Articles

Most recent articles on Cetrorelix

Most cited articles on Cetrorelix

Review articles on Cetrorelix

Articles on Cetrorelix in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Cetrorelix

Images of Cetrorelix

Photos of Cetrorelix

Podcasts & MP3s on Cetrorelix

Videos on Cetrorelix

Evidence Based Medicine

Cochrane Collaboration on Cetrorelix

Bandolier on Cetrorelix

TRIP on Cetrorelix

Clinical Trials

Ongoing Trials on Cetrorelix at Clinical Trials.gov

Trial results on Cetrorelix

Clinical Trials on Cetrorelix at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cetrorelix

NICE Guidance on Cetrorelix

NHS PRODIGY Guidance

FDA on Cetrorelix

CDC on Cetrorelix

Books

Books on Cetrorelix

News

Cetrorelix in the news

Be alerted to news on Cetrorelix

News trends on Cetrorelix

Commentary

Blogs on Cetrorelix

Definitions

Definitions of Cetrorelix

Patient Resources / Community

Patient resources on Cetrorelix

Discussion groups on Cetrorelix

Patient Handouts on Cetrorelix

Directions to Hospitals Treating Cetrorelix

Risk calculators and risk factors for Cetrorelix

Healthcare Provider Resources

Symptoms of Cetrorelix

Causes & Risk Factors for Cetrorelix

Diagnostic studies for Cetrorelix

Treatment of Cetrorelix

Continuing Medical Education (CME)

CME Programs on Cetrorelix

International

Cetrorelix en Espanol

Cetrorelix en Francais

Business

Cetrorelix in the Marketplace

Patents on Cetrorelix

Experimental / Informatics

List of terms related to Cetrorelix

Cetrorelix acetate is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). A synthetic decapeptide, it is used to treat hormone-sensitive cancers of the prostate and breast (in pre-/perimenopausal women) and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, cetrorelix is used in assisted reproduction. The drug works by blocking the action of GnRH upon the pituitary, thus rapidly suppressing the production and action of LH and FSH. It is administered as a daily or weekly subcutaneous injection.

Cetrorelix is marketed by Solvay Pharmaceuticals as Cetrotide.[1]

References

Template:Sex hormones Template:Pituitary and hypothalamic hormones and analogues

Template:WikiDoc Sources